Dunad Therapeutics, Ltd.

Jay Bradner is to leave Novartis after seven years as its leader of drug discovery, a departure which will add to a changing of the guard already underway at the Swiss-headquartered pharma company.

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big

Recently formed Dunad Therapeutics, Ltd. has pulled off something of a coup by signing a major licensing deal with Novartis AG for its platform to be used to develop orally bioavailable covalent a